tradingkey.logo

Emergent BioSolutions Inc

EBS
View Detailed Chart
10.160USD
-0.110-1.07%
Close 11/07, 16:00ETQuotes delayed by 15 min
535.43MMarket Cap
7.05P/E TTM

Emergent BioSolutions Inc

10.160
-0.110-1.07%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.07%

5 Days

-18.59%

1 Month

+2.73%

6 Months

+59.75%

Year to Date

+6.28%

1 Year

-13.68%

View Detailed Chart

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Emergent BioSolutions Inc's Score

Industry at a Glance

Industry Ranking
80 / 159
Overall Ranking
232 / 4614
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Hold
Current Rating
13.500
Target Price
+32.87%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Emergent BioSolutions Inc Highlights

StrengthsRisks
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Overvalued
The company’s latest PE is 7.15, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 37.92M shares, decreasing 12.20% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 0.00 shares of this stock.

Emergent BioSolutions Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Emergent BioSolutions Inc Info

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Ticker SymbolEBS
CompanyEmergent BioSolutions Inc
CEOMr. Joseph C. (Joe) Papa
Websitehttps://emergentbiosolutions.com/
KeyAI